Key Developments: Proteome Sciences PLC (PRM.L)
67.00GBp
20 May 2013
-0.25p (-0.37%)
66.75p
--
--
--
115,748
336,814
74.00p
24.00p
Latest Key Developments (Source: Significant Developments)
Proteome Sciences PLC Comments On FY 2013 Revenue Guidance
Proteome Sciences PLC announced that for fiscal 2013, it expects strong revenue growth across the Company's three main divisions. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of GBP6.5 million for fiscal 2013. Full Article
Proteome Sciences PLC To Collaborate With CHDI Foundation On Huntington's Disease Research
Proteome Sciences PLC announced that they will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington's disease. Initially, Proteome will provide PS Biomarker Services protein profiling to CHDI's research programs. The analyses will be performed at Proteome's facility in Frankfurt am Main (Germany), which is certified according to the international quality standards of ISO 9001:2008. Full Article
Proteome Sciences PLC Grants License to Randox Laboratori
Proteome Sciences PLC announced that it granted a non-exclusive license to Randox Laboratories ("Randox") of Crumlin, UK for its portfolio of stroke biomarkers. Under the terms of the Agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Financial terms provide Proteome Sciences with seven digit (US dollar) license and development milestones together with double digit royalties on sales. Full Article
Proteome Sciences PLC Announces Completion Of Alzheimer's Plasma Biomarker Study
Proteome Sciences PLC announced the completion of , 1,000 sample Alzheimer's Disease (AD) biomarker validation study. Preliminary results indicate that these biomarkers have potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of this debilitating disease. Three biomarker panels in blood, each containing between 11 and 16 proteins, have been identified which can discriminate between mild cognitive impairment (a syndrome often preceding AD), AD and control groups respectively. Proteome Sciences is filing further intellectual property around these panels which include and combine markers covered by existing patents with additional newly validated biomarkers. It is estimated that 60% of people with AD have not been properly diagnosed and therefore are not being given vital drugs and care. The capability to distinguish between the levels and progression of the disease will enable drug developers to substantially improve patient care and people with mild cognitive impairment are likely to benefit the from such disease-modifying drugs. Full Article
Proteome Sciences PLC Announces Holdings In Company
Proteome Sciences PLC announced that it has been informed that Cubana Investments Limited has been acquired by Vulpes Life Science Fund. Following this transaction, and as of March 9, 2012, Cubana no longer has a voting interest in the Company and Vulpes has voting control over 33,100,000 ordinary shares in the Company representing 17.19% of the Company's voting share capital. Full Article
Proteome Sciences PLC Announces Promising Hits Against Alzheimer's Target And Further Progress Elsewhere
Proteome Sciences PLC announced that selected compounds, previously identified as potential inhibitors against CK1δ, have been tested in cells and have shown strong activity. Further IP has been filed to cover the results which the Directors believe will considerably increase the value of the CK1δ programme. The next stage, which has already started, is to further refine the new compounds and to move to an in-vivo model system to complete lead optimisation in mid 2012. With such supporting data, CK1δ should be quickly adopted and licensed to a pharmaceutical company as a drug development programme for which Proteome Sciences would receive fees, milestones and royalties. The increased commercial and academic interest focusing on tau protein has required the Company to expand the number of tau phosphorylation assays in AD to 10, including some CK1δ specific sites. Full Article
Proteome Sciences PLC Announces Master Research Agreement With Siena Biotech S.p.A
Proteome Sciences PLC announced that it has entered into a Master Research Agreement (MRA) with Siena Biotech S.p.A. (Siena Biotech) under which it has been retained as preferred supplier of protein and peptide biomarker services for Siena's drug development programs. In the first project under the MRA Proteome will apply its PS Biomarker Services to deliver a detailed analysis of post-translational modifications on a neurological disease-related protein. Proteome will apply sample preparation and analytical methods combined with Orbitrap Velos mass spectrometry to deliver a high-density PTM map of Siena Biotech's protein target. Full Article
Proteome Sciences PLC Announces Collaboration With Buck Institute For Research On Aging
Proteome Sciences PLC announced that it will collaborate with Buck Institute for Research on Aging (Buck) to develop personalized molecular tests for estrogen receptor alpha (ERa) aimed at improving outcomes in breast cancer. Under the agreement, Proteome will support development of clinical mass spectrometry assays measuring molecular changes in ERathat have been shown to be associated with response to anti-estrogen therapies in breast cancer. Full Article
Proteome Sciences PLC And Moffitt Cancer Center Collaborate On Clinical Mass Spectrometry Assays For Assessment Of Cancer Patients
Proteome Sciences PLC announced that it has entered into a collaboration agreement with Moffitt Cancer Center (Moffitt). Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling and repair pathway proteins that can be adapted for tumour biopsy analysis in the clinic. Full Article
Proteome Sciences PLC Secures Contract
Proteome Sciences PLC announced that it is a participant in a new project, that has been awarded a EUR6.99 million Framework 7 Grant over the next two years to study the effects of environmental contamination in health and developmental disorders in children. Proteome Sciences will receive EUR530,058 for its contribution to the project. The main aim of the DENAMIC project is to develop tools and methods to monitor neurotoxic effects of environmental pollutants that may cause adverse effects on cognitive skills and developmental disorders in children (including Attention Deficit Hyperactivity Disorder, autism and anxiety disorders). Proteome Sciences will investigate the effects of neurotoxic chemicals on proteins, peptides and biochemical pathways in cell models and tissue to generate a database of protein biomarkers associated with chemical exposure. The study will be undertaken with mass spectrometry using TMT labelled peptides and from which biomarker assays will be developed. This approach enables validation of protein biomarkers with relatively high throughput, avoiding the need of immunoassay development and having the advantages of being able to verify biomarkers when antibodies are unavailable. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
